Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 959-967

  Ikonomidis, Ignatios ^a   Tzortzis, Stavros ^a   Lekakis, John ^a   Paraskevaidis, Ioannis ^a   Dasou, Pinelopi ^a   Parissis, John ^a   Nikolaou, Maria ^a   Markantonis, Sophia L ^a   Katsimbri, Pelagia ^a   Skarantavos, Grigoris ^a   Andreadou, Ioanna ^a   Anastasiou Nana, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anakinra; Apoptosis; Interleukin 1; Myocardial deformation; Oxidative stress; Rheumatoid arthritis

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CASPASE 9; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAS ANTIGEN; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE IMPAIRMENT; HEART PERFORMANCE; HEART STRESS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TISSUE DOPPLER IMAGING; TREATMENT DURATION; TREATMENT RESPONSE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD95; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASPASE 9; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER; FAS LIGAND PROTEIN; FEMALE; GREECE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIUM; PREDNISOLONE; RECEPTORS, INTERLEUKIN-1; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 80155192997     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-02-0117     Document Type: Article

References (43)

1. Lee Y, Gustafsson Å. Role of apoptosis in cardiovascular disease. Apoptosis 2009; 14: 536-548.
2. Bryant D, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-1381.
3. Sayen MR, et al. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am J Physiol Cell Physiol 2003; 284: C562-C570.
4. Wang J, et al. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Natl Acad Sci USA 2001; 98: 4038-4043.
5. Tsuboi M, et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134: 222-231.
6. Lemonnier J, et al. Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin 1. Am J Pathol 2001; 158: 1833-1842.
7. Chen D-Y, et al. Elevated levels of soluble Fas (APO-1, CD95), soluble Fas ligand, and matrix metalloproteinase-3 in sera from patients with active untreated adult onset Still's disease. Clin Rheumatol 2007; 26: 393-400.
8. Ates A, et al. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 2004; 23: 421-425.
9. Nozawa K, et al. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 1997; 40: 1126-1129.
10. Tanaka M, et al. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
11. Yamagouchi S, et al. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 1999; 83: 1500-1503.
12. Okuyama M, et al. Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol 1997; 79: 1698-1701.
13. Adamopoulos S, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102-106.
14. Ikonomidis I, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117: 2662-2669.
15. Ikonomidis I, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart 2009; 95: 1502-1507.
16. Ikonomidis I, et al. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a 'multimarker' approach? Thromb Haemost 2006; 95: 397-398.
17. Takahashi T, et al. Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells. Microvasc Res 2007; 73: 29-34.
18. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Letters 1994; 350: 9-12.
19. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res. 2007; 75: 291-302.
20. Dinarello CA. Interleukin-1 and Interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
21. Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 2009; 57: 165-176.
22. Sironi M, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142: 549-553.
23. Abbate A, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-2683.
24. Lekakis JP, et al. Genetic variations of the endothelial nitric oxide synthase gene are related to increased levels of C-reactive protein and macrophage-colony stimulating-factor in patients with coronary artery disease. Thromb Haemost 2006; 96: 520-528.
25. Tedgui A, Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001; 86: 420-426.
26. Katsaros KM, et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis. Thromb Haemost 2011; 105: 883-891.
27. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
28. Degterev A, et al. A decade of caspases. Oncogene 2003; 22: 8543-8567.
29. Nesic O, et al. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma 2001; 18: 947-956.
30. Sun CC, et al. Interleukin-1 receptor antagonist (IL-1RA) prevents apoptosis in ex vivo expansion of human limbal epithelial cells cultivated on human amniotic membrane. Stem Cells 2006; 24: 2130 -2139.
31. Garcia JH, et al. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol 1995; 147: 1477-1486.
32. Mulcahy NJ, et al. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol. 2003; 140: 471-476.
33. Abbate A, et al. Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction. Am J Cardiol 2010; 105: 1371-1377.
34. Zitta K, et al. Interleukin-1beta regulates cell proliferation and activity of extracellular matrix remodelling enzymes in cultured primary pig heart cells. Biochem Biophys Res Commun. 2010; 399: 542-547.
35. Zell R, et al. TNF-alpha and IL-1alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Moll Cell Biochem 1997; 177: 61-67.
36. Li S, et al. TNF-a initiated oxidative/nitrative stress mediated cardiomyocyte apoptosis in traumatic animals. Apoptosis 2007; 12: 1795-1802.
37. Tian B, et al. Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis. Am J Physiol Heart Circ Physiol. 2002; 283: H1958-1967.
38. Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 2010; 342: 325-339.
39. Kuckleburg CJ, et al. Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and -9 and generation of reactive oxygen species. Thromb Haemost 2008; 99: 363-372.
40. Raza K, et al. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 2005; 32: 754-756.
41. Weinstein DM, et al. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 2000; 294: 396-401.
42. Ikonomidis I, et al. Additive prognostic value of interleukin-6 at peak phase of dobutamine stress echocardiography in patients with coronary artery disease. A 6-year follow-up study. Am Heart J 2008; 156: 269-276.
43. Carlson DL, et al. Caspase inhibition reduces cardiac myocyte dyshomeostasis and improves cardiac contractile function after major burn injury. J Appl Physiol 2007; 103: 323-330.